focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
31% up ;-)
I remember as few years back, it multi-bagged extremely fast. A bit like now, fuelling the rocket and then booooom!!!
So why are we only a 3m market cap??
I just got quoted 2.7 for a large buy
2.5 now !
Think of the bigger picture. The company is well positioned to move forward with the new staff and experienced Non Exec Director.
The hardest contracts to get are the first ones, now we have Cancer Research UK as a client and it could easily lead to more business in the future. As it only lasts a couple of months it's unlikely to have massive value, but the next one might.
100% today? Maybe just maybe on that RNs
Flying now !
Wow. That’s some RNS. Let’s see 4p today
What we known is PYC hit record revenues for year ended June 2022 and has cash for 2-3yrs + and an exciting time going forward ( see last result)
See Kidlingtons reply from broker last week clog
Are we allowed to know what the contract is worth ?
Well, that lasted all off a few hours till news arrived.
Aleta’s mission is to create cell therapeutics that provide robust and durable clinical benefit for patients suffering from advanced hematologic cancers and refractory solid tumors. Aleta’s CAR-T Engager technology incorporates potent multi-antigen targeting, optimal T cell fitness, and persistence to aggressively attack cancers. We use this technology to build programs that solve specific clinical issues, including cell therapy relapses due to antigen loss and the challenge of overcoming solid tumor heterogeneity. Our lead development program has won landmark clinical support from Cancer Research UK and will enter Phase1/2 trials in 2022.
No value to deal thou.
Deal is to last till end of calendar year, so not long then?
Contract award
Physiomics plc (AIM: PYC), the consultancy company offering expertise in mathematical modelling and simulation to enable smarter decision making in drug development for the biopharma industry, is pleased to announce that it has signed an agreement to work with Cancer Research UK.
Physiomics will use its PKPD modelling capabilities to support the Cancer Research UK sponsored early phase clinical development of ALETA-001, a CAR-T cell engager candidate for the treatment of blood cancers developed by Aleta Biotherapeutics. The PKPD modelling project is expected to be completed during this calendar year.
Dr Jim Millen, CEO said: "We are delighted to be working with Cancer Research UK, the world's leading cancer charity. Although we have previously worked with clients whose early clinical trials are sponsored by Cancer Research UK's Centre for Drug Development, this project marks the first occasion on which Physiomics has worked directly with Cancer Research UK."
#PYC I am officially hacked off now. Won’t be tweeting about it till they come up with substantial news. The ‘biggest pipeline’ in coy history translates into destruction of the SP from what I can see? ????. Board, put hand in pockets & show some confidence..over n out.
Wont be posting here either till news
where is he ?
I assume that the person mentioned in this tweet from Bicycle : https://twitter.com/Bicycle_tx/status/1579491809168064513?s=20&t=fHdA20MTrGV4vNOJMfoUtA is the person that is a fan of PYC ?
EVG nice news
I have no idea about why buys cant go thru, i thought all stockbrokers were the same?
No substantial buy for sometime, but at least we stayed flat for the entire week, which has never happened before to my knowledge.
Many thanks
Judging By those answers it seems to be a really good propect going forward, particularly points 3 , 4 and 8
The trial for NHS finished September for recruitment so looking forward to outcomes this calendar year
I am trying to buy on Hargreaves but there is no quote
Why is that?
Thanks Kid' for you effort and taking the time...
Thanks Kidlington, at least they replied to you and answered some of your questions.
Annual report out and AGM announcement for 22nd November.
https://www.physiomics.co.uk/wp-content/uploads/2022/09/Final-Results-for-the-year-ended-30-June-2022-and-Date-of-AGM_29-09-2022.pdf